Today’s guest is someone I personally met on LinkedIn. He is the former Vice President of Corporate Development and Strategy at Synthetic Genomics where he was responsible for defining, evolving and implementing SGI’s strategy across all of its franchises with a focus on value creation. In that context, he was involved in managing a portfolio of internal initiatives, strategic partnerships, and transactions along with leading investor and media relations.

He had a nine-year tenure on Wall Street, most recently with J.P. Morgan’s healthcare investment banking group where he advised clients on mergers and acquisitions as well as debt and equity financings. In his career on Wall Street, he executed over $20 billion in transactions.

He has an MBA from Carnegie Mellon University’s Tepper School of Business and my B.S. in Mechanical Engineering from Case Western Reserve University. He is also a Founder/Director of the 32/21 Foundation, a college scholarship charity founded in his brother’s honor.